CartiHeal, a Kfar Saba, Israel-based developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, secured $2.5M in funding.
Bioventus made the investment, which complements CartiHeal’s latest financing round, led by aMoon, together with Johnson & Johnson Innovation, Peregrine Ventures, and Elron, and brings the total round to $21M.
The company intends to use the funds to advance its ongoing Agili-C IDE clinical study.
Led by CEO Nir Altschuler, CartiHeal is a medical device company that develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
The Agili-C™ IDE study is set to include a minimum of 250 patients in US and OUS centers, aiming for a PMA submission. The trial’s objective is to demonstrate the superiority of the Agili-C™ implant over the surgical standard of care (microfracture and debridement) for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes.